When purchasing a Mycoplasma pneumoniae nucleic acid kit, how do you determine whether the clinical verification data provided by the manufacturer is sufficient for laboratory access?

The access audit looks not only at the product specifications, but also at whether the method meets the intended use and laboratory quality requirements. Reference intervals alone are often inadequate, as nucleic acid qualitative or quantitative items focus more on coincidence rates, detection limits, linearity, specificity, interference, and methodological comparisons with the original record. It is recommended that manufacturers provide clinical reports, sample sources, positive-negative composition, comparison methods, inconsistent sample handling, and registration tests or related performance data. If the original comparison data is missing, at least confirm the pairing with the existing validated method in the laboratory, and keep a complete record for review.

The sample size for performance validation is recommended to be stratified by risk: precision is available at low to medium to high target concentrations or typical clinical samples, repeated about 20 times per level, and covers batches and operators; detection limits can be gradient dilution and 10 to 20 independent weakly positive samples, while adding common inhibitors; cross-reactions cover at least common pathogens of the respiratory tract, co-infection and interfering substances. Clinical comparison can first include dozens to hundreds of retrospective samples, stratified by negative and different load positive, calculating the agreement rate and reviewing the inconsistent samples. If you only look at domestic low prices, you also need to take into account the cold chain, delivery date, quality control products and failure retesting costs.